Story · Medicine & Biotech
Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice
1 outlet · first reported by GEN Genetic Engineering News on
Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits. Now, a new study shows that a… (GEN Genetic Engineering News)
Coverage, in order
-
Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice
Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits. Now, a new study shows that a…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.